Sorafenib and Vorinostat in Treating Patients With Advanced Liver Cancer

Phase 1 Completed 16 enrolled Virginia Commonwealth University Massey Cancer Center · collab

Non-randomizedParallel-groupOpen-labelTreatment

Summary

This phase I trial is studying the side effects and best dose of vorinostat when given together with sorafenib tosylate in treating patients with advanced liver cancer. Sorafenib tosylate and vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth or by blocking blood flow to the tumor.

Timeline

Start: 2010-08-10
Primary completion: 2017-02-02
Completion: 2019-07-18

Publications

Results Gordon SW, McGuire WP 3rd, Shafer DA, Sterling RK, Lee HM, Matherly SC, Roberts JD, Bose P, Tombes MB, Shrader EE, Ryan AA, Kmieciak M, Nguyen T, Deng X, Bandyopadhyay D, Dent P, Poklepovic AS. Phase I Study of Sorafenib and Vorinostat in Advanced Hepatocellular Carcinoma. Am J Clin Oncol. 2019 Aug;42(8):649-654. doi: 10.1097/COC.0000000000000567.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Sorafenib	Small molecule	200 mg	Oral
Subject	Sorafenib	Small molecule	400 mg	Oral
Subject	Vorinostat	Small molecule	100 mg	Oral
Subject	Vorinostat	Small molecule	200 mg	Oral
Subject	Vorinostat	Small molecule	300 mg	Oral
Subject	Vorinostat	Small molecule	400 mg	Oral

Sorafenib and Vorinostat in Treating Patients With Advanced Liver Cancer

Summary

Timeline

Publications

Drugs

Indications